CoChat

The effect of glucagon‐like peptide‐1 receptor agonists on serum uric acid concentration: A systematic review and meta‐analysis

Open access
Najafi, Sara, Bahrami, Milad, Butler, Alexandra E., Sahebkar, Amirhossein · 2022 · British Journal of Clinical Pharmacology
Cited by 39

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

Abstract

Aims: Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) are a class of medications mainly used for the treatment of type 2 diabetes. They improve glucose tolerance, increase insulin secretion and induce weight loss. There is controversy about the effect of GLP‐1 RAs on serum uric acid (SUA) concentration. Our systematic review aims to objectively answer whether GLP‐1 RAs affect SUA levels. Methods: We performed a systematic search on PubMed, Web of Science, Embase, Scopus and Google Scholar datasets up to 27August 2021 with a language restriction of English only. Randomized controlled trials, observational studies, uncontrolled trials and conference abstracts were included. Studies with insufficient data, irrelevant types of study and follow‐up duration of less than a month were excluded from the review. After critical appraisal by the Joanna Briggs Institute checklists, articles underwent data extraction using a prespecified Microsoft Excel sheet. Results: Of 1004 identified studies, 17 were eligible for inclusion in this systematic review. Pre‐ to post‐administration analysis of GLP‐1 RA effects on SUA demonstrated that GLP‐1 RAs could significantly reduce SUA concentration (difference in means −0.341, SE 0.063, P value <0.001). However, when compared to placebo, GLP‐1RAs did not perform any better in lowering SUA concentration (difference in means −0.455, SE 0.259, P value 0.079). Surprisingly, the active controls, which included insulin, metformin, sodium‐glucose co‐transporter 2 (SGLT‐2) inhibitors and dipeptidyl‐peptidase 4 inhibitors, did outperform GLP‐1 RAs in reducing SUA concentration (difference in means 0.250, SE 0.038, P value <0.001). Conclusions: Administration of GLP‐1 RAs can result in a significant reduction in SUA concentration. However, this reduction is less than that seen with the use of insulin, metformin and SGLT‐2 inhibitors.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/bcp.15344

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 19 references

Cited by

See all 39

Metadata

Authors
Najafi, S., Bahrami, M., Butler, A. E., & Sahebkar, A.
Venue
British Journal of Clinical Pharmacology
Publisher
Wiley
Published
2022-04-17
Volume
88
Issue
8
Pages
3627-3637
ISSN
  • 0306-5251 (ISSN-L)
  • 1365-2125
OpenAlex
W4224068676
Cited by
39
References
19
FWCI
1.35
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The effect of glucagon‐like peptide‐1 receptor agonists on serum uric acid concentration: A systematic review and meta‐analysis. https://app.cochat.ai/papers/10.1111/bcp.15344
The paper
Najafi, S., Bahrami, M., Butler, A. E., & Sahebkar, A. (2022). The effect of glucagon‐like peptide‐1 receptor agonists on serum uric acid concentration: A systematic review and meta‐analysis. British Journal of Clinical Pharmacology. https://doi.org/10.1111/bcp.15344

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.